Joslin Diabetes Center and Truman Medical Centers Join Forces to Test the Joslin Clinical Analytic Tool (JCAT™)
Truman Medical Centers (TMC) and Joslin Diabetes Center, an affiliate of Harvard Medical School, have launched a pilot program to test the capabilities of a novel new tool called the Joslin Clinical Analytical Tool (JCAT™). Using JCAT, healthcare providers can systematically gauge the effectiveness of diabetes care, identify gaps in care earlier, and, when appropriate, implement changes to the treatment plan, thus reducing the risks for complications and improving health outcomes for those with diabetes.
“We are delighted to be working with Truman Medical Centers on this project. TMC has a well-documented track record of delivering innovative programs to help people live healthier lives,” said Director of Medical Affairs, Healthcare Services, Joslin Diabetes Center and Associate Professor, Harvard Medical School, Rich Jackson, MD. “We are also very impressed by TMC’s commitment to its community and the great work that it continues in this realm as well. TMC is an ideal partner for implementing an innovative program such as JCAT.”
Developed by Joslin physicians, JCAT makes it easier for healthcare providers to better gauge the effectiveness of the diabetes care in their practice by focusing directly on patient health outcomes. It identifies specific areas for intervention that are likely to be the most effective in improving health outcomes and reducing the cost of care. Unlike other quality measures, JCAT provides a roadmap to improvement specific enough to be actionable and pragmatic.
“TMC is a leader in providing top quality care to those with chronic illness. Each year, nearly 70 percent of TMC’s patient base has at least one major chronic disease, with diabetes being the second largest group behind hypertension,” said TMC Executive Vice President of Clinical Coordination, Mark McPhee, MD. “Partnering with Joslin Diabetes Center allows TMC to make innovative advancements in the methods of care for people with diabetes at the primary care level while at the same time exposing the JCAT to a unique patient base.”
Earlier results, presented at the 2013 73rd Scientific Sessions of the American Diabetes Association, showed significant improvement in diabetes outcomes for patients whose physicians participated in a JCAT study.